STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4073 by analyst upside · 2026-08-12
FULC
Fulcrum Therapeutics, Inc.
Healthcare · Market Cap $282M · P/E 0x
ANALYST PRICE TARGET
-7.9%
implied upside to consensus target
Current Price $3.69
Consensus Target $3.4
Bull Target $4.0
Bear Target $3.0
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
0
Hold
4
Sell
1
52-Week Low $2.83
52-Week High $15.74
YTD Return -66.2%
FUNDAMENTALS
Market Cap $282M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.21
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.83
52-Week High $15.74
Current Price $3.69
Bear Target $3.0
Bull Target $4.0
● Now $3.69 ● Target $3.4
TRADING DATA
Avg Volume 2.6M
YTD Return -66.2%
Analyst Count 5
Consensus Hold
Upside to Target -7.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Fulcrum Therapeutics, Inc. (FULC) is currently trading at $3.69 with a Wall Street consensus price target of $3.4, which is 7.9% below the current price over the next 12 months. 5 analysts currently cover FULC, with a consensus rating of Hold - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.0, while the most cautious has a target of $3.0.

FULC operates in the Healthcare sector with a market capitalisation of $282M. The stock is down 66.2% year-to-date and is currently trading near the lower end of its 52-week range of $2.83 – $15.74.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for FULC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ↓ Downgrade
Overweight → Underweight 2026-06-03 43% win rate (7 calls)
Stifel ↓ Downgrade
Buy → Hold 2026-06-02 Building track record
Piper Sandler ↓ Downgrade
Overweight → Underweight 2026-06-02 14% win rate (7 calls)
Truist Securities ↓ Downgrade
Buy → Hold 2026-06-02 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-06-02 29% win rate (7 calls)
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-06-02 31% win rate (48 calls)
JP Morgan ● Initiated
Overweight 2026-01-12 43% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2025-12-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
25/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →